Swiss National Bank Reduces Stock Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

Swiss National Bank cut its stake in TG Therapeutics, Inc. (NASDAQ:TGTX) by 0.7% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 286,600 shares of the biopharmaceutical company’s stock after selling 2,000 shares during the quarter. Swiss National Bank owned about 0.19% of TG Therapeutics worth $6,704,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Sei Investments Co. purchased a new stake in TG Therapeutics in the first quarter worth about $591,000. Russell Investments Group Ltd. grew its stake in shares of TG Therapeutics by 133.5% in the first quarter. Russell Investments Group Ltd. now owns 52,339 shares of the biopharmaceutical company’s stock worth $796,000 after acquiring an additional 29,923 shares during the last quarter. Lazard Asset Management LLC purchased a new position in shares of TG Therapeutics in the 1st quarter worth about $91,000. Price T Rowe Associates Inc. MD boosted its stake in TG Therapeutics by 6.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 85,603 shares of the biopharmaceutical company’s stock worth $1,303,000 after purchasing an additional 5,015 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. grew its position in TG Therapeutics by 29.9% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 524,861 shares of the biopharmaceutical company’s stock valued at $7,983,000 after purchasing an additional 120,699 shares during the last quarter. 58.58% of the stock is owned by hedge funds and other institutional investors.

TG Therapeutics Stock Down 1.0 %

NASDAQ TGTX opened at $34.26 on Wednesday. TG Therapeutics, Inc. has a 12 month low of $12.30 and a 12 month high of $36.84. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. The stock has a market cap of $5.33 billion, a PE ratio of -342.60 and a beta of 2.19. The stock’s 50 day moving average is $25.81 and its 200 day moving average is $21.83.

TG Therapeutics (NASDAQ:TGTX) last issued its earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01). The company had revenue of $83.90 million for the quarter, compared to the consensus estimate of $81.68 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. TG Therapeutics’s revenue was down 49.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.73 EPS. Research analysts predict that TG Therapeutics, Inc. will post 0.17 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on TGTX. B. Riley boosted their price target on TG Therapeutics from $29.00 to $34.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. The Goldman Sachs Group boosted their price target on TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. HC Wainwright upped their price objective on TG Therapeutics from $49.00 to $55.00 and gave the stock a “buy” rating in a research note on Tuesday, November 5th. JPMorgan Chase & Co. boosted their price target on TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a report on Monday. Finally, TD Cowen assumed coverage on TG Therapeutics in a research note on Tuesday, October 29th. They set a “buy” rating and a $50.00 price objective for the company. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $40.67.

Insider Buying and Selling at TG Therapeutics

In related news, Director Sagar Lonial sold 5,000 shares of the company’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $30.44, for a total transaction of $152,200.00. Following the sale, the director now owns 100,195 shares of the company’s stock, valued at $3,049,935.80. This represents a 4.75 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 10.50% of the company’s stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.